Our results, which link specific high-risk CTLA-4 genotypes to elevated sCTLA-4 levels and disease severity, provide a plausible genetic explanation for the observed efficacy of CTLA-4 blockade in a subset of HCC patients. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.